EntreMed, Inc. is a NASDAQ listed public company with a stock code: ENMD. It is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global oncology market. Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently initiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer and a Phase 2 study in soft tissue sarcoma. The Company has a wholly owned subsidiary, EntreMed (Beijing) Co. Ltd., in Beijing, China with headquarters in Chaoyang business district. Additional information about EntreMed is available on the Company\'s web site at www.entremed.com. EntreMed, Inc.为美国NASDQ上市（股票代码ENMD）生物制药公司，致力于小分子靶向治疗肿瘤的创新药物的开发与产业化。目前主要在研药物ENMD-2076为一多靶点抗肿瘤药，可选择性抑制激光蛋白激酶、血管生成激酶抑与肿瘤细胞分裂相关的蛋白激酶。目前已在美国完成针对不同实体瘤、多发性骨髓瘤、白血病等的1期临床试验。研究表面单药对卵巢癌、乳腺癌、肝癌、肾癌、软组织肉瘤等具有明显的活性。现正开展一项针对卵巢癌的国际多中心2期临床试验。另外，公司近期启动了一项关于ENMD-2076治疗三阴乳腺癌的2期临床试验和一项治疗软组织肉瘤的2期临床。英创远达（北京）生物医药科技有限公司为EntreMed在北京设立的全资子公司，总部位于北京市朝阳区。更多信息请登录公司网站 www.entremed.com 了解。
